Skip to main content
profile image
Selected Works of Walter J. Urba, MD, PhD
Article
A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).
Journal of Clinical Oncology (2019)
  • David B. Page, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Isaac K Kim, Earle A. Chiles Research Institute at Providence Cancer Instutute, Portland, OR;
  • Brie Chun, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • William L Redmond, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Maritza Martel, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Motomi Mori, Oregon Health & Science University
  • Dottie Wadell, Patient Advocate, Portland, OR;
  • Nicole Moxon, Providence Cancer Center, Portland, OR;
  • Staci L. Mellinger, Providence Cancer Center, Portland, OR;
  • Walter John Urba, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR;
  • Ayca Gucalp, Memorial Sloan Kettering Cancer Center
  • Tiffany A. Traina, Memorial Sloan Kettering Cancer Center
Link
Disciplines
Publication Date
May 20, 2019
DOI
10.1200/JCO.2019.37.15_SUPPL.TPS1106
Citation Information
David B. Page, Isaac K Kim, Brie Chun, William L Redmond, et al.. "A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC)." Journal of Clinical Oncology Vol. 37 (2019)
Available at: http://works.bepress.com/walter-urba/287/